The Day Lab is based in the UCL Division of Medicine. It forms part of the Centre for Precision Healthcare and the Department of Experimental and Translational Medicine.
The Day Lab has a sustained track record in the creation and application of new technology applied to regenerative medicine. This spans invention, development, public engagement, clinical translation and commercialisation. Notable achievements include pioneering clinical translation of a novel class III medical device, consisting of a biomaterial developed by the group, into an MHRA approved Phase I/IIb trial (UCL's first regulated trial for a novel biomaterial) and the EU funded AMELIE project (www.amelie-project.eu), UCL’s largest, most ambitious translational tissue engineering study to date comprising of a UCL invented tissue engineered product to be investigated in a Phase I/IIb trial involving 64 patients delivered across six European countries.
The group conducts internationally-leading research supported by cross-disciplinary research collaborations with other UCL groups in the Faculties of Engineering (Department of Mechanical Engineering), Life Sciences (Division of Biosciences, School of Pharmacy), Mathematical & Physical Sciences (Chemistry Department, Physics & Astronomy Department), Institute of Cardiovascular Science (The Hatter Cardiovascular Institute), and Medical Sciences (Eastman Dental Institute, Division of Surgery), as well as clinical, surgical and nursing collaborations at the affiliated University College London Hospital.
The group works closely with the UCL Translational Research Office, UCL Innovation & Enterprise, and UCL Business Ltd to facilitate clinical translation and commercialization of our exciting and innovative technology.
This site contains up to date information on the current activities of the group.